Avolition Characterizes the Chronic Fatigue Experienced in Quiescent Inflammatory Bowel Disease

Archive ouverte

Gabriel-Segard, Tristan | Boltri, Margherita | Barrau, Mathilde | Massoubre, Catherine | Paul, Stéphane | Roblin, Xavier

Edité par CCSD ; MDPI -

International audience. Background and Aims: Avolition is a symptom responsible for a high burden in patients suffering from psychiatric diseases. It refers to a motivation loss for initiating and maintaining goal-directed activities, often called fatigue by patients. Fatigue is a widespread complaint of patients suffering from inflammatory bowel disease (IBD), significantly impacting patients’ well-being, even during the quiescent stage of the disease. We here address the hypothesis that fatigue experienced by IBD patients is associated with motivational impairment. Methods: Patients presenting IBD (n = 110) in a quiescent stage of Crohn’s disease (CD) (n = 60) and ulcerative colitis (UC) (n = 50) were enrolled and classified following their declared experience of fatigue (n = 58) or not (n = 52). Patients were phenotyped using self-administered scales for fatigue experience, bowel disease disability, quality of life and mental health symptoms. Results: The self-administered negative symptoms scale scores identified avolition as a specific feature of fatigue experience: fatigued vs. no-fatigue in the CD group (3.806 vs. 2.103; p = 0.003) and in the UC group (2.815 vs. 1.174; p = 0.003). This difference is independent of current depressive disorder and previous history of depressive disorder. Avolition associates and correlates with the experience of fatigue (r = 0.49) in multivariate analysis. Conclusions: To tackle the question of fatigue in IBD, research should consider investigating the biological mechanisms implicating intestinal physiopathology of IBD in the impairment of brain structure involved in motivation. This may open new fields for treatment in targeting structures of the brain reward system.

Consulter en ligne

Suggestions

Du même auteur

What Should We Know about Drug Levels and Therapeutic Drug Monitoring during Pregnancy and Breastfeeding in Inflammatory Bowel Disease under Biologic Therapy?

Archive ouverte | Barrau, Mathilde | CCSD

International audience. Data on the real long-term influences of in utero drug exposure in pregnant women on childhood development are scarce and remain not well determined and depend on the duration of in utero dru...

Serum calprotectin is useful to confirm inflammatory bowel disease activity but not to predict relapse

Archive ouverte | Veyrard, Pauline | CCSD

International audience. Aim: Serum calprotectin (SC), a novel biomarker of inflammatory bowel diseases (IBD), has been recently investigated with conflicting results. The purpose of this study was to assess the abil...

Development of Antibodies to Ustekinumab Is Associated with Loss of Response in Patients with Inflammatory Bowel Disease

Archive ouverte | Roblin, Xavier | CCSD

International audience. Monitoring of anti-drug antibodies in patients on ustekinumab is not routinely recommended in patients with inflammatory bowel disease (IBD) due to low rates of immunogenicity. Aim of study: ...

Chargement des enrichissements...